Can I Get HIV from Someone on Biktarvy Treatment?

Understanding Biktarvy and HIV Transmission

Biktarvy, a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection, is a complete treatment regimen. It contains three different medicines: bictegravir, emtricitabine, and tenofovir alafenamide. HIV medicines cannot cure HIV/AIDS; however, they help people with HIV live longer, healthier lives by reducing the risk of HIV transmission. If someone is consistently taking Biktarvy and maintaining an undetectable viral load, the risk of HIV transmission significantly decreases.

For HIV viral load to be considered undetectable, it must be brought to a level that cannot be detected by a standard viral load test. This level is typically below 20 copies/mL or 40 copies/mL, depending on the test used. Once this level is achieved and maintained for at least six months, the risk of transmitting HIV is considered negligible.

Factors Influencing the Risk of HIV Transmission

Length of Treatment: The duration someone has been on Biktarvy is a critical factor in determining the viral load. Consistent, long-term treatment is necessary to achieve and maintain an undetectable viral load. Viral Load Monitoring: Consistent viral load monitoring by healthcare professionals ensures that the treatment is effective and the viral load remains undetectable. Risk Sexual Activity: Engaging in high-risk sexual activity without the use of protection, such as condoms, increases the risk of HIV transmission, even if the viral load is undetectable. PrEP (Pre-Exposure Prophylaxis): Taking PrEP, which is medicine taken to prevent getting HIV, is highly effective at reducing the risk of HIV transmission. When taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99%, and by at least 74% among people who inject drugs.

Why Take PrEP

PrEP is a preventive measure for individuals at risk of HIV infection, whether through sexual activity or injection drug use. It works by stopping HIV from taking hold and spreading throughout your body. Currently, there are two FDA-approved daily oral medications for PrEP, and a long-acting injectable form of PrEP has also been approved by the FDA.

Conclusion

Consistent use of Biktarvy and maintaining an undetectable viral load significantly reduce the risk of HIV transmission. However, other factors, such as engaging in high-risk sexual activity without protection, can increase the risk. Using PrEP and adhering to healthcare recommendations further reduces the risk of HIV transmission. If you are on Biktarvy and have any concerns about the risk of HIV transmission, consult your healthcare provider for guidance and support.